Benitec Biopharma (BNTC) EBIT (2019 - 2025)
Historic EBIT for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$9.8 million.
- Benitec Biopharma's EBIT fell 7725.31% to -$9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$41.8 million, marking a year-over-year decrease of 8570.48%. This contributed to the annual value of -$41.8 million for FY2025, which is 8570.48% down from last year.
- Latest data reveals that Benitec Biopharma reported EBIT of -$9.8 million as of Q2 2025, which was down 7725.31% from -$15.3 million recorded in Q1 2025.
- Benitec Biopharma's 5-year EBIT high stood at -$3.5 million for Q1 2022, and its period low was -$15.3 million during Q1 2025.
- In the last 5 years, Benitec Biopharma's EBIT had a median value of -$4.8 million in 2021 and averaged -$6.0 million.
- In the last 5 years, Benitec Biopharma's EBIT surged by 877.93% in 2022 and then plummeted by 27032.12% in 2025.
- Quarter analysis of 5 years shows Benitec Biopharma's EBIT stood at -$4.8 million in 2021, then decreased by 16.03% to -$5.6 million in 2022, then decreased by 23.48% to -$6.9 million in 2023, then tumbled by 55.98% to -$10.8 million in 2024, then increased by 8.99% to -$9.8 million in 2025.
- Its EBIT stands at -$9.8 million for Q2 2025, versus -$15.3 million for Q1 2025 and -$10.8 million for Q4 2024.